Press Release

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/49 August 05, 2026 To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol – BIOCON Subject: Press Release on financial results for the quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “Biocon Q1FY27 Total Income at Rs 4,391 Cr, Up 9%; EBITDA at Rs 902 Cr; Net Profit at Rs 141 Cr; Biopharma Revenue Up 17%” pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter ended June 30, 2026. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the above information on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Enclosed: Press Release and Fact Sheet PRESS RELEASE Biocon Q1FY27 Total Income at Rs 4,391 Cr, Up 9%; EBITDA at Rs 902 Cr; Net Profit at Rs 141 Cr; Biopharma Revenue Up 17% Bengaluru, Karnataka, India: August 5, 2026: Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal first quarter ended June 30, 2026. FINANCIAL PERFORMANCE • Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business. • Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets. o Biosimilars revenue increased 16% YoY to Rs 2,855 crore. Note: Revenue contribution as a % of Revenue o Generics revenue increased 21% from Operations YoY Rs 760 crore. • Services revenue decreased 16% YoY to Rs 736 crore due to continued impact of challenges faced last year. • Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%, supported by improved profitability in the Biopharma business, which helped offset continued challenges in the Services business. • Interest cost at Rs 213 crore, down 23% YoY from Rs 277 crore, following the actions taken to strengthen Biocon’s balance sheet. • Net Profit before exceptionals was Rs 145 crore. LEADERSHIP COMMENTS “Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.” – Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited “Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya™️ and Aukelso™️ (biosimilar Denosumab), Yesafili™️ (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.” – Shreehas Tambe, CEO & Managing Director, Biocon Limited “As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth. My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.” – Siddharth Mittal, CEO & Managing Director, Syngene International Limited FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY27 In Rs Crore Particulars Q1FY27 Q1FY26 YoY (%) INCOME Biosimilars 2,855 2,458 16% Generics 760 630 21% Biopharma (Biosimilars + 3,615 3,088 17% Generics) Services 736 875 (16%) Inter-segment (15) (21) 28% Revenue from operations# 4,336 3,942 10% Other income 55 80 (31%) Total Income 4,391 4,022 9% Net R&D Expenses 240 205 17% EBITDA 902 846 7% EBITDA Margins 21% 21% PBT (before Exceptional items) 141 114 24% PBT (after Exceptional items^) 128 97 32% Net Profit (before Exceptional 145 42 245% Net Profit (Reported) 141 31 355% Figures above are rounded off to the nearest Crore; % based on absolute numbers. Notes to financials above: #Revenue from operations includes licensing income ^Exceptional items during Q1FY27 and Q1FY26 amount to Rs (13) crore and Rs (17) crore, respectively ^^Net of tax and minority interest, exceptional items during Q1FY27 and Q1FY26 amounted to Rs. (4) crore and Rs. (11) crore respectively, resulting in a Net Profit of Rs 141 crore and Rs 31 crore, respectively BUSINESS PERFORMANCE - Biopharma North America • Growth in North America region was driven by the ramp-up of recently launched biosimilars, including Bosaya™ and Aukelso™ (biosimilar Denosumab) in the U.S., coupled with stable performance in the oncology portfolio. • Commercialized Yesafili™ (aflibercept-jbvf) in the U.S., in August, as an interchangeable biosimilar Aflibercept. • Secured Health Canada Notice of Compliance (NOC) for Yesintek® (biosimilar Ustekinumab) autoinjector pen. • Commercialized generic Liraglutide in the U.S. Europe • Commercialized Evfraxy® (biosimilar Denosumab), for bone health, across multiple European markets. • Commercialized Abevmy® (biosimilar Bevacizumab) from oncology portfolio in Czech Republic and Switzerland. Emerging Markets • Expanded market access through multiple product approvals and commercial partnerships across Emerging Market countries. • Secured approval for Yesafili™ as Malaysia’s first biosimilar Aflibercept. • Maintained strong market leadership for biosimilar Bevacizumab franchise in Brazil. BUSINESS PERFORMANCE - Services • Signed MoU with BRIC-Translational Health Science and Technology Institute (THSTI) for early and late-phase clinical development, translational research, and bioanalytical sciences. The collaboration will enable the evaluation and execution of First-in-Human (FIH) and Phase I clinical programs, along with bioanalytical, biomarker and patient-based clinical research programs. • Continued to strengthen Syn.AI, an AI-enabled scientific platform for accelerating drug discovery services, by developing giga scale virtual screening capabilities. This will enable screening and prioritizing larger libraries of molecules, accelerating the identification of promising drug candidates. Board Updates • Bobby Parikh has completed his term as an Independent Director of the Company with effect from the close of business hours of July 22, 2026. • Nicholas Haggar shall complete his term as an Independent Director of the Company with effect from the conclusion of the ensuing 48th Annual General Meeting of the Company scheduled to be held on August 6, 2026. • [Showing first 8,000 characters — download PDF for full document]